MD Anderson Cancer Center-University of Texas
Welcome,         Profile    Billing    Logout  
 7 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yao, James
SWOG-S0518, NCT00569127: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Active, not recruiting
3
427
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Samilstin, Sandostatin, Sandostatin LAR, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
01/15
01/25
Wang, Michael
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Recruiting
3
71
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
PRESent-3, NCT05789537: A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors

Recruiting
2
12
Europe, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia B With Inhibitor, Hemophilia B
09/25
10/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Recruiting
2
120
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
03/26
06/26
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
ONCT-808-101, NCT05588440: A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Recruiting
1/2
57
US
ONCT-808, Bridging Therapy
Oncternal Therapeutics, Inc
Relapsed/Refractory Aggressive B-Cell Malignancies
12/26
12/37
VISTA, NCT05619471: VIO Imaging for Skin Tissue Assessment

Completed
N/A
65
US
VIO Imaging
Enspectra Health, National Cancer Institute (NCI), National Institutes of Health (NIH)
Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities, Skin Cancer
08/23
08/23
NCT05940948: [Trial of device that is not approved or cleared by the U.S. FDA]

Withheld
N/A
600
NA
TruScore
[Redacted], Golden State Dermatology
Skin Cancer, Skin Melanoma, Skin Cancers - Squamous Cell Carcinoma, Skin Cancer, Non-Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Lesion
 
 
NCT03853486: ATHN 9: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
NCT05568459: A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Recruiting
N/A
120
Europe, Canada, US
Non-Interventional
Regeneron Pharmaceuticals
Hemophilia B
04/26
04/26
Addison, Alicia
No trials found

Download Options